Last year, Doherty Institute researchers made global news with a world‑first approach utilising mRNA technology to target and wake up hidden HIV cells. Now, this approach will be advanced thanks to $1.2M boost NHMRC IDEAS Grants Scheme.
Find out more 🔗 https://bit.ly/4mvc8YJ
Australia has been recognised by @who.int for meeting strict international standards for the safe containment of poliovirus samples. This certification reflects Australia’s ongoing role in global polio surveillance and eradication efforts.
Find out more 🔗 https://bit.ly/3Qe7odW
New research shows getting your annual flu vaccine can protect you from seasonal influenza strains and prime your immune system to respond to future strains, even some that emerge decades later.
Find out more 🔗 https://bit.ly/4saTNBw
A portable device built on CRISPR technology can now detect multiple STIs, including syphilis, from a single sample in under an hour. Dr Shivani Pasricha explains how CRISPR could revolutionise STI diagnostics and improve patient care.
Find out more 🔗 https://bit.ly/4bTwwOq
Interested in helping research looking at immune responses to vaccines against mosquito-borne diseases? If you’re 18 - 60 years with no serious immune problems, you may be eligible for our study in Melbourne.
🔗 For more info visit https://bit.ly/47JVRIl
Your generation can fight Chlamydia. Ready to help?
Chlamydia is one of the most common STIs worldwide. In more than 80% of cases, individuals have no symptoms and are unaware they are infected.
If you are aged 18-29 years, you may be eligible to join this vaccine trial.
🔗 https://bit.ly/4ajaZ1Z
Your generation can fight Chlamydia. Ready to help?
Chlamydia is one of the most common STIs worldwide. In more than 80% of cases, individuals have no symptoms and are unaware they are infected.
If you are aged 18-29 years, you may be eligible to join this vaccine trial.
🔗 https://bit.ly/4ajaZ1Z
🔬 50 years of electron microscopy (EM) at VIDRL, from Australia’s first HIV ultrastructural images in the 1980s to the first local images of SARS‑CoV‑2. EM is a vital tool for detecting and characterising pathogens during outbreaks.
Find out more 🔗 https://bit.ly/4sLZOoK
Interested in helping research looking at immune responses to vaccines against mosquito-borne diseases? If you’re 18 - 60 years with no serious immune problems, you may be eligible for our study in Melbourne.
🔗 For more info visit https://bit.ly/47JVRIl
Your generation can fight Chlamydia. Ready to help?
Chlamydia is one of the most common STIs worldwide. In more than 80% of cases, individuals have no symptoms and are unaware they are infected.
If you are aged 18-29 years, you may be eligible to join this vaccine trial.
🔗 https://bit.ly/4ajaZ1Z
Interested in helping research looking at immune responses to vaccines against mosquito-borne diseases? If you’re 18 - 60 years with no serious immune problems, you may be eligible for our study in Melbourne.
🔗 For more info visit https://bit.ly/47JVRIl
A new collaborative study has developed HIV‑seq, a tool that profiles rare HIV‑infected cells in people living with HIV. The breakthrough offers new insight into how these cells behave and could help guide future treatment strategies.
https://bit.ly/3OQVhmA
A world-first portable point-of-care test detects syphilis, herpes, chlamydia & gonorrhoea simultaneously in under an hour — helping reduce misdiagnosis and cut transmission.
https://bit.ly/4bjVlnl
@unimelb.edu.au
Your generation can fight Chlamydia. Ready to help?
Chlamydia is one of the most common STIs worldwide. In more than 80% of cases, individuals have no symptoms and are unaware they are infected.
If you are aged 18-29 years, you may be eligible to join this vaccine trial.
🔗 https://bit.ly/4ajaZ1Z
Interested in helping research looking at immune responses to vaccines against mosquito-borne diseases? If you’re 18 - 60 years with no serious immune problems, you may be eligible for our study in Melbourne.
🔗 For more info visit https://bit.ly/47JVRIl
Could one vaccine protect against multiple deadly bacterial infections? Researchers at the Doherty Institute and Monash University have developed a promising preclinical vaccine targeting both golden staph and pneumococcal disease, as reported in Nature Microbiology.
🔗 https://bit.ly/4aBEiM8
Your generation can fight Chlamydia. Ready to help?
Chlamydia is one of the most common STIs worldwide. In more than 80% of cases, individuals have no symptoms and are unaware they are infected.
If you are aged 18-29 years, you may be eligible to join this vaccine trial.
🔗 https://bit.ly/4ajaZ1Z
New research uncovers gamma‑delta T cells send a crucial signal through production of cytokine interleukin‑4, that helps the body fight parasitic infection, malaria. These findings offer new insights for boosting future vaccines and treatments.
Find out more 🔗 https://bit.ly/4anRANm
Interested in helping research looking at immune responses to vaccines against mosquito-borne diseases? If you’re 18 years or older with no serious immune problems, you may be eligible for our study in Melbourne.
🔗 For more info visit https://bit.ly/47JVRIl
A new way to tackle antibiotic‑resistant infections. Researchers have engineered antibodies that target pseudaminic acid — a sugar found only on bacterial cells — helping the immune system precisely identify and destroy drug‑resistant bacteria.
https://bit.ly/45PSbVx
With Nipah making headlines again, it’s important to ask: what are the facts?
Nipah virus is not new, cases remain limited, and outbreaks over the past two decades have been closely managed. In public health, following the facts matters.
🔗 https://bit.ly/4qXDU1l
Exhausted T cells and tissue‑resident memory T cells may look alike, but a new study finds key differences across cancers that could impact immunotherapy. One recognises tumour “tags,” the other reflects past infections, like flu or COVID-19, and must be deliberately engaged.
https://bit.ly/3M365Ni
What’s the latest on COVID-19 antivirals? Community Advisory Board member Mohamed Mohideen chats with infectious diseases physician A/Prof Katherine Gibney, in our new video series, Questions from the Community.
📹 Watch here: https://bit.ly/4syjmh0
2025 was a surprising year for flu, with cases extending beyond winter, a new subclade-K variant emerging and a boost in cases at the start of Summer. What does this activity tell us about the year ahead?
🔗 www.doherty.edu.au/news-events/news/2025-th...
Understanding COVID-19 vaccines: eligibility, timing and protecting at risk groups. Community Advisory Board member Mohamed Mohideen chats with infectious diseases physician A/Prof Katherine Gibney in our new video series.
📹 Watch here: https://bit.ly/3LlDnqA
Where are we at with COVID-19 now? Community Advisory Board member Mohamed Mohideen chats with infectious diseases physician A/Prof Katherine Gibney, in our new video series, Questions from the Community.
📹 Watch here: https://youtu.be/zXJrCyEOoqk?si=519ezWI8pNyt7j5O
Doherty Institute secures $12.9M NHMRC Ideas Grants for 9 projects tackling antimicrobial resistance, TB, HIV, cancer immunology & immune biology—advancing new ways to fight infections & immune-related diseases.
🔗 https://bit.ly/4aJ6gas
Doherty Institute researchers have secured a $5M NHMRC Synergy Grant to uncover immune changes during pregnancy—insights that could improve maternal & newborn health worldwide.
🔗 Read more: www.doherty.edu.au/news-events/news/5-milli...
2025 has been a surprising year for influenza, with case activity extending beyond winter and a new variant H3N2 emerging.
Experts from @whofluccmelb.bsky.social unpack 2025 insights and explain what an unusual flu season means for us looking ahead to 2026.
https://bit.ly/496uwRu
A new approach using possum poo surveillance and cutting-edge genomics can provide an early-warning system to flag emerging Buruli ulcer hot spots before human cases occur.
www.doherty.edu.au/news-events/news/early-w...